USPTO serial 88469477
HYLEUKIN-7
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- O'BRIEN, JENNIFER LYNN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with HYLEUKIN-7?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Seongnamsi, Gyeonggi, KR
Seongnamsi, Gyeonggi, KR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
James R Menker
James R Menker Holley & Menker, PAPO Box 331937Atlantic Beach, FL 32233UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Antibiotics; Anti-cancer preparations; Anti-inflammatory preparations, namely, anti-inflammatory gels, ointments, salves, sprays, creams, pills, powders, granules, tablets, capsules, depots, suppository, syrup, tinctures and emulsion; Antiviral agent against human papilloma virus; Blood solvent for medical purposes, namely, blood plasma, albumin, globulin, fibrinogen, thrombocyte and platelets; Cardiovascular pharmaceutical preparations for the treatment and prevention of heart and vascular diseases; Dermatological pharmaceutical products; DNA vaccines; Drugs for medical purposes, namely, pharmaceutical drug preparations for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Injectable pharmaceuticals for medical purposes, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Medicines for sensory organs, namely, pharmaceutical preparations for the prevention, treatment, and cure of diseases and conditions impacting the eyes, ears, nose, mouth and nervous system; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and compositions for the treatment and prevention of cancer; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for anticancer immunotherapy; Pharmaceutical preparations for digestive organs, namely, for the prevention, treatment, and cure of diseases and conditions impacting digestive organs; Pharmaceutical preparations for gene therapy; Pharmaceutical preparations for immunomodulatory purposes, namely, for the regulation of immune functions; Pharmaceutical preparations for immunotherapy; Pharmaceutical preparations for preventing and treating obese; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for the prevention of osteoporosis; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the treatment of cardiovascular disease; Pharmaceutical preparations for the treatment of cervical cancer; Pharmaceutical preparations for the treatment of cervical intraepithelial neoplasia; Pharmaceutical preparations for the treatment of cervical pre-cancer; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of head and neck cancer; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for the treatment of multiple sclerosis; Pharmaceutical preparations for the treatment of osteoporosis; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating hypertension; Pharmaceutical preparations for treating malignant tumours; Pharmaceutical preparations for urogenital organs; Pharmaceutical preparations for wounds; Pharmaceutical products and preparations, namely, for the treatment and prevention of human papilloma virus infectious disease, cancer and cervical intraepithelial neoplasia; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of cancer; Pharmaceutical products for the treatment of infectious diseases; Pharmaceutical products for the treatment of viral and infectious diseases; Pharmaceutical products for the treatment of viral diseases; Preventive vaccines; Preventive vaccines against human papilloma virus infections; Therapeutic vaccines; Vaccines; Pharmaceutical preparations for the treatment of lymphopenia; Immunoglobulin fusion protein pharmaceutical preparations, namely, antibodyfusion proteins for the treatment of cancer | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 25, 2021 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jan 25, 2021 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 23, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Apr 28, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 28, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 8, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 25, 2020 | ALIE | ASSIGNED TO LIE | — |
| Mar 19, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 18, 2020 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 18, 2020 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 18, 2020 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 18, 2020 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 24, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 24, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Feb 24, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 24, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 24, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 24, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 24, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 24, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 26, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 26, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 26, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 20, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 24, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 15, 2019 | NWAP | NEW APPLICATION ENTERED | — |